Biotechnology
Medical
Female CEOs

GlycoMimetics

$13.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.23 (1.79%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell GlycoMimetics and other stocks, options, ETFs, and crypto commission-free!

About

GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. Read More The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Employees
50
Headquarters
Rockville, Maryland
Founded
2003
Market Cap
555.48M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
378.51K
High Today
$13.17
Low Today
$12.74
Open Price
$12.74
Volume
81.95K
52 Week High
$19.20
52 Week Low
$8.29

Collections

Biotechnology
Medical
Female CEOs
Health
Technology
2014 IPO
US

News

Simply Wall St7h

What Should We Expect From GlycoMimetics, Inc.’s (NASDAQ:GLYC) Earnings Over The Next Few Years?

GlycoMimetics, Inc.’s (NASDAQ:GLYC) latest earnings announcement in December 2018 indicated that losses became smaller relative to the prior year’s level – great news for investors Below is my commentary, albeit very simple and high-level, on how market analysts view GlycoMimetics’s earnings growth outlook over the next few years and whether the future looks brighter. I will be looking at earnings excluding extraordinary items to exclude one-off activities to get a better understanding of the underlying dri...

4
MarketBeatMar 7

Stock Price, News, & Analysis for GlycoMimetics

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-sel...

7
Simply Wall StFeb 28

Have Insiders Been Selling GlycoMimetics, Inc. (NASDAQ:GLYC) Shares This Year?

We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we’d be remiss not to mention that insider sales have been known to precede tough periods for a business. So shareholders might well want to know whether insiders have been buying or selling shares in GlycoMimetics, Inc. (NASDAQ:GLYC). What Is Insider Buying? Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sel...

58

Earnings

-$0.37
-$0.33
-$0.28
-$0.24
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.